Cipla is preparing to launch the drug Favipiravir for the treatment of COVID patients.
New Delhi:
Pharmaceutical company Cipla is set to launch Favipiravir, developed by the Council for Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement Thursday.
An unpatented antiviral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for the treatment of patients with COVID-19, especially in mild and moderate cases.
The CSIR-Indian Institute of Chemical Technology (CSIR-IICT) developed a cost effective process using locally available chemicals to synthesize this active pharmaceutical ingredient (API) and transferred the technology to Cipla.
“Cipla has stepped up the process at its manufacturing facility and contacted DCGI (Drug Controller General of India) for approval to launch the product in India. As DCGI has granted restricted emergency use of Favipiravir in the country, Cipla is now ready to launch the product to help patients suffering from COVID-19, ”the statement said.
Commenting on the development, CSIR-IICR Director S Chandrashekhar said the technology is very efficient and makes it affordable and allows Cipla to manufacture large quantities of the product in a short period of time.
CSIR CEO Shekhar C Mande observed that they were working with industry to develop rapid solutions and products for COVID-19 mitigation and this partnership with Cipla is an example of how CSIR pledged to bring reused drugs soon.
(This story was not edited by GalacticGaming staff and is auto-generated from a syndicated feed.)
